Jennison Associates LLC Exelixis, Inc. Transaction History

Jennison Associates LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$19.25 - $24.13 $15,688 - $19,665	815 Added 0.5%	164,200 $3.94 Million
Q3 2023 Oct 31, 2023	BUY	$19.04 - $22.74 $930,484 - $1.11 Million	48,870 Added 42.68%	163,385 $3.57 Million
Q2 2023 Aug 03, 2023	BUY	$18.17 - $20.48 $2.08 Million - $2.35 Million	114,515 New	114,515 $2.19 Million
Q3 2018 Nov 08, 2018	SELL	$15.87 - $22.4 $50.7 Million - $71.6 Million	-3,194,242 Closed	0 $0
Q2 2018 Aug 02, 2018	SELL	$18.56 - $22.45 $37.8 Million - $45.7 Million	-2,035,040 Reduced 38.92%	3,194,242 $68.7 Million
Q1 2018 Apr 20, 2018	BUY	$22.15 - $31.89 $22.2 Million - $31.9 Million	1,000,521 Added 23.66%	5,229,282 $116 Million
Q4 2017 Jan 25, 2018	BUY	$24.23 - $30.93 $28.3 Million - $36.1 Million	1,167,758 Added 38.15%	4,228,761 $129 Million
Q3 2017 Nov 03, 2017	BUY	$23.35 - $29.24 $71.5 Million - $89.5 Million	3,061,003	3,061,003 $74.2 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.